Search Results - "Záčková, Daniela"

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia by Pfirrmann, Markus, Clark, Richard E., Prejzner, Witold, Lauseker, Michael, Baccarani, Michele, Saussele, Susanne, Guilhot, François, Heibl, Sonja, Hehlmann, Rüdiger, Faber, Edgar, Turkina, Anna, Ossenkoppele, Gert, Höglund, Martin, Zaritskey, Andrey, Griskevicius, Laimonas, Olsson-Strömberg, Ulla, Everaus, Hele, Koskenvesa, Perttu, Labar, Boris, Sacha, Tomasz, Zackova, Daniela, Cervantes, Francisco, Colita, Adriana, Zupan, Irena, Bogdanovic, Andrija, Castagnetti, Fausto, Guilhot, Joëlle, Hasford, Joerg, Hochhaus, Andreas, Hoffmann, Verena S.

“…Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase…”
Get full text

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission by Machova Polakova, Katerina, Zizkova, Hana, Zuna, Jan, Motlova, Eliska, Hovorkova, Lenka, Gottschalk, Andrea, Glauche, Ingmar, Koblihova, Jitka, Pecherkova, Pavla, Klamova, Hana, Stastna Markova, Marketa, Srbova, Dana, Benesova, Adela, Polivkova, Vaclava, Jurcek, Tomas, Zackova, Daniela, Mayer, Jiri, Ernst, Thomas, Mahon, Francois X., Saussele, Susanne, Roeder, Ingo, Cross, Nicholas C. P., Hochhaus, Andreas

“…This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on…”
Get full text

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF by Žáčková, Daniela, Semerád, Lukáš, Faber, Edgar, Klamová, Hana, Stejskal, Lukáš, Bělohlávková, Petra, Karas, Michal, Cmunt, Eduard, Černá, Olga, Procházková, Jiřina, Čičátková, Petra, Kvetková, Anežka, Horňák, Tomáš, Skoumalová, Ivana, Srbová, Dana, Šálek, Cyril, Buffa, David, Voglová, Jaroslava, Jurček, Tomáš, Folta, Adam, Ježíšková, Ivana, Žižková, Hana, Machová Poláková, Kateřina, Papajík, Tomáš, Žák, Pavel, Jindra, Pavel, Svobodník, Adam, Štěpánová, Radka, Mayer, Jiří

Get full text

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI by Richter, Johan, Lübking, Anna, Söderlund, Stina, Lotfi, Kourosh, Markevärn, Berit, Själander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Žáčková, Daniela, Mayer, Jiří, Olsson-Strömberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, Koskenvesa, Perttu

Get full text

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia by Racil, Zdenek, Razga, Filip, Drapalova, Jana, Buresova, Lucie, Zackova, Daniela, Palackova, Martina, Semerad, Lukas, Malaskova, Ludmila, Haluzik, Martin, Mayer, Jiri

Get full text

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data by Belohlavkova, Petra, Zackova, Daniela, Klamova, Hana, Faber, Edgar, Karas, Michal, Stejskal, Lukas, Cmunt, Eduard, Cerna, Olga, Jeziskova, Ivana, Machova Polakova, Katerina, Zak, Pavel, Jurkova, Tereza, Chrapava, Marika, Mayer, Jiri

“…Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world…”
Get full text

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study by Horňák, Tomáš, Semerád, Lukáš, Žáčková, Daniela, Weinbergerová, Barbora, Šustková, Zuzana, Procházková, Jiřina, Bělohlávková, Petra, Stejskal, Lukáš, Rohoň, Peter, Faber, Edgar, Žák, Pavel, Mayer, Jiří, Ráčil, Zdeněk

Get full text

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy by Racil, Zdenek, Koritakova, Eva, Sacha, Tomasz, Klamova, Hana, Belohlavkova, Petra, Faber, Edgar, Rea, Delphine, Malaskova, Ludmila, Prochazkova, Jirina, Zackova, Daniela, Voglova, Jaroslava, Wącław, Joanna, Cetkovsky, Petr, Zak, Pavel, Mayer, Jiri

Get full text

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects by Culen, Martin, Borsky, Marek, Nemethova, Veronika, Razga, Filip, Smejkal, Jiri, Jurcek, Tomas, Dvorakova, Dana, Zackova, Daniela, Weinbergerova, Barbora, Semerad, Lukas, Sadovnik, Irina, Eisenwort, Gregor, Herrmann, Harald, Valent, Peter, Mayer, Jiri, Racil, Zdenek

“…Little is known about the function and phenotype of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) or about specific markers that discriminate…”
Get full text

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients by Belohlavkova, Petra, Vrbacky, Filip, Voglova, Jaroslava, Racil, Zdenek, Zackova, Daniela, Hrochova, Katerina, Malakova, Jana, Mayer, Jiri, Zak, Pavel

“…Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport…”
Get full text

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes by Perusini, Maria Agustina, Žáčková, Daniela, Kim, Taehyung, Pagnano, Katia, Pavlovsky, Carolina, Ježíšková, Ivana, Kvetková, Anežka, Jurček, Tomáš, Kim, Jaeyoon, Yoo, Youngseok, Yi, Seongyoon, Lee, Hyewon, Kim, Kyoung Ha, Chang, Myunghee, Capo-Chichi, Jose-Mario, Medeiros, Jessie J. F., Arruda, Andrea, Minden, Mark, Zhang, Zhaolei, Abelson, Sagi, Mayer, Jiri, Hwan Kim, Dennis Dong

“…•Somatic mutations were more frequently detected in patients with failure/resistance/progression than in optimal responders.•The presence of mutations,…”
Get full text

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy by Pavlík, Tomáš, Janoušová, Eva, Pospíšil, Zdeněk, Mužík, Jan, Záčková, Daniela, Ráčil, Zdeněk, Klamová, Hana, Cetkovský, Petr, Trněný, Marek, Mayer, Jiří, Dušek, Ladislav

“…The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML…”
Get full text

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE by Semerad, Lukas, Žáčková, Daniela, Belohlavkova, Petra, Voglova, Jaroslava, Žák, Pavel, Faber, Edgar, Papajik, Tomas, Skoumalova, Ivana, Karas, Michal, Jindra, Pavel, Klamová, Hana, Salek, Cyril, Srbová, Dana, Zizkova, Hana, Stejskal, Lukas, Cerna, Olga, Cmunt, Eduard, Cicatkova, Petra, Kvetkova, Anezka, Hornak, Tomas, Jeziskova, Ivana, Jurcek, Tomas, Weinbergerová, Barbora, Prochazkova, Jirina, Machova Polakova, Katerina, Svobodnik, Adam, Stepanova, Radka, Mayer, Jiri

Get full text

Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis by Poláková, Kateřina Machová, Polívková, Václava, Rulcová, Jana, Klamová, Hana, Jurček, Tomáš, Dvořáková, Dana, Žáčková, Daniela, Pospíšil, Zdeněk, Mayer, Jiří, Moravcová, Jana

“…Objective Of 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at…”
Get full text

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia by Razga, Filip, Racil, Zdenek, Machova Polakova, Katerina, Buresova, Lucie, Klamova, Hana, Zackova, Daniela, Dvorakova, Dana, Polivkova, Vaclava, Cetkovsky, Petr, Mayer, Jiri

Get full text

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels by Klamová, Hana, Poláková, Kateřina Machová, Mužík, Jan, Ráčil, Zdeněk, Žáčková, Daniela, Steinerová, Kateřina, Karas, Michal, Faber, Edgar, Demečková, Eva, Michalovičová‐Sninská, Zuzana, Voglová, Jaroslava, Demitrovičová, Ľudmila, Mikušková, Eva, Tóthová, Elena, Chudej, Juraj, Markuljak, Imrich, Cmunt, Eduard, Moravcová, Jana, Dvořáková, Dana, Michalová, Kyra, Jarošová, Marie, Šťastná, Markéta Marková, Cetkovský, Petr, DuŠek, Ladislav, Koza, Vladimír, Trněný, Marek, Indrák, Karel

“…We evaluated responses to the treatment and long‐term outcomes of chronic myeloid leukemia patients treated with imatinib as first‐line treatment in routine…”
Get full text

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia by Knight, Andrea, Piskacek, Martin, Jurajda, Michal, Prochazkova, Jirina, Racil, Zdenek, Zackova, Daniela, Mayer, Jiri

“…Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we…”
Get full text

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence by Dahlen, Torsten, Kockerols, Camille, Ferreira, Germano, Westerweel, Peter E., Mayer, Jiří, Sahmoud, Tarek, Wormser, David, Yau, Lillian, Žácková, Daniela

“…Introduction: Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with chronic myeloid leukemia in chronic phase (CML-CP). The advent of…”
Get full text

Novel Illumina‐based next generation sequencing approach with one‐round amplification provides early and reliable detection of BCR‐ABL1 kinase domain mutations in chronic myeloid leukemia by Romzova, Marianna, Smitalova, Dagmar, Tom, Nikola, Jurcek, Tomas, Culen, Martin, Zackova, Daniela, Mayer, Jiri, Racil, Zdenek

“…Summary The occurrence of mutations in the BCR‐ABL1 kinase domain (KD) can lead to treatment resistance in chronic myeloid leukaemia patients. Nowadays,…”
Get full text

A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts by Folta, Adam, Jurcek, Tomas, Kubesova, Blanka, Zackova, Daniela, Mayer, Jiri, Jeziskova, Ivana

“…The detection and quantification of BCR-ABL1 transcripts play a key role in therapy management of chronic myeloid leukemia (CML) patients treated with tyrosine…”
Get full text